A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study to assess the safety and tolerability of VGL101 in
subjects with documentation of a gene mutation in the CSF1R gene for the treatment of
adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and to
evaluate the effects of VGL101 on imaging and biomarkers of disease progression in subjects
with ALSP. Participants will receive infusions of VGL101 approximately every 4 weeks for 1
year.